At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 530 enrolled
Drug / intervention
Ramucirumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
In Brief
A Phase 3 clinical trial evaluating Ramucirumab, Docetaxel, and 1 other intervention for Urothelial Carcinoma. Completed, enrolled 530 participants across 141 sites in 23 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma
CountriesAustralia, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJul 2015
Primary CompletionApr 2017
Study CompletionJul 2022
TodayJul 2026
First PostedApr 24, 2015
Enrollment StartJul 13, 2015
Primary CompletionApr 21, 2017
Study CompletionJul 26, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.2 years ago
Interventions
Ramucirumabdrug
Administered IV
Docetaxeldrug
Administered IV
Placebodrug
Administered IV